Caspian Journal of Internal Medicine
1
Caspian J Intern Med
Medical Sciences
http://caspjim.com
1
admin
2008-6164
2008-6172
8
10.22088/cjim
14
8888
13
en
jalali
1400
11
1
gregorian
2022
2
1
13
2
online
1
fulltext
en
Curcumin as adjuvant therapy to improve remission in myeloma patients: A pilot randomized clinical trial
Hematology
Hematology
Original Article
Original Article
<div><span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="color:#0000ff;"><em><strong>Background:</strong> </em></span>The treatment for ineligible transplant multiple myeloma is melphalan prednisone. Curcumin has an anti-inflammatory and antiangiogenesis in cancer-directed to nuclear factor-kappa B (NF-kB) pathway. Interleukin 6 (IL-6), vascular endothelial growth factor (VEGF), tumor necrosis factor-alpha (TNF-α), C-reactive protein (CRP), and lactate dehydrogenase (LDH) were also involved in the pathogenesis of myeloma. No clinical study has evaluated the efficacy of curcumin in myeloma patients.To evaluate the efficacy of curcumin as adjuvant into melphalan prednisone in myeloma patients<br>
<span style="color:#0000ff;"><strong><em>Methods:</em></strong></span> 33 myeloma patients at Dr. Kariadi General Hospital, Semarang, Indonesia during 2016-2017 were randomly assigned single-blindedly into MPC (n=17) and control group (n=16). The MPC group was treated with melphalan 4 mg/m2, prednisone 40 mg/m2 for 7 days, and curcumin 8 gram daily for 28 days. The MP control group was treated with melphalan, prednisone, and placebo. The primary endpoint was the overall remission. Pre- and post-treatment was examined for NF-κB, VEGF, TNF-α, IL-6, LDH, and CRP levels All data analyses were per protocol.<br>
<span style="color:#0000ff;"><em><strong>Results:</strong></em></span> There was a significant difference in overall remission between the MPC and MP control groups [75%vs 33.3%, x<sup>2</sup>=6.89, P=0.009]. A significant decrease of NF-κB, VEGF, TNF-α levels were shown in the MPC group compared with the MP control group. There was a significant decrease in IL-6 levels in a subgroup analysis of the MPC group. TNF-α levels had a significant correlation with remission [OR=1.35; (95%CI=1.03-1.76); P=0.03]. <br>
<span style="color:#0000ff;"><strong><em>Conclusion: </em></strong></span>Curcumin has an efficacy in improving overall remission and decreasing NF-κB, VEGF, TNF-α, and IL-6 levels in myeloma patients<strong>.</strong></span></span></div>
myeloma, remission, NF-κB, VEGF, TNF-α, and IL-6
375
384
http://caspjim.com/browse.php?a_code=A-10-1603-1&slc_lang=en&sid=1
Damai
Santosa
santosaiva@yahoo.com
100319475328460036528
100319475328460036528
Yes
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Indonesia
Catharina
Suharti
hemasemarang@gmail.com
100319475328460036529
100319475328460036529
No
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Indonesia
Ignatius
Riwanto
iriwanto@gmail.com
100319475328460036530
100319475328460036530
No
Department of Surgery, Faculty of Medicine, Diponegoro University, Indonesia
Edi
Dharmana
edidharmana@yahoo.com
100319475328460036531
100319475328460036531
No
Department of Parasitology, Faculty of Medicine, Diponegoro University, Indonesia
Eko
Adhi Pangarsa
ekopangarsa90@gmail.com
100319475328460036532
100319475328460036532
No
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Indonesia
Budi
Setiawan
boedhi_smg73@yahoo.com
100319475328460036533
100319475328460036533
No
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Indonesia
Suyono
Suyono
100319475328460036534
100319475328460036534
No
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Jawa Tengah, Indonesia
Mika
Lumban Tobing
hemasemarang@yahoo.com
100319475328460036535
100319475328460036535
No
Division of Hematology-Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Diponegoro University/Dr. Kariadi General Hospital, Indonesia
Suhartono
Suhartono
santosaiva@yahoo.com
100319475328460036536
100319475328460036536
No
Department of Environmental Health, Faculty of Public Health, Diponegoro University, Jawa Tengah, Indonesia
Soeharyo
Hadisaputro
prof_haryo@yahoo.co.id
100319475328460036537
100319475328460036537
No
Division of Topical and Infectious Disease, Department of Internal Medicine, Faculty of Medicine, Diponegoro University, Indonesia